key: cord-0840660-lx08jxwt
authors: Reisinger, Alexander C.; Hermann, Josef; Vagena, Fotini R.; Hackl, Gerald; Eller, Philipp
title: Tuberculosis sepsis after tocilizumab treatment
date: 2020-06-05
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2020.05.030
sha: b748525560c836f9262f0eca29f779af84a99046
doc_id: 840660
cord_uid: lx08jxwt

nan

To the Editor In the current coronavirus 2019 pandemic, tocilizumab has gained widespread attention as a therapeutic option for the treatment of severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) infection (1, 2). Tocilizumab is an interleukin-6 receptor (IL-6R) antagonist previously used for various rheumatologic diseases, and now applied to treat cytokine release syndrome in COVID-19. IL-6R antagonists, however, may lead to higher susceptibility for opportunistic infections and increase the risk for pneumonia, urinary tract infections, and cellulitis (3).

Here, we present the case of a 46-year old woman who presented with epigastric pain to our emergency department. Two weeks before admission, she had received her first treatment with tocilizumab for systemic sclerosis and systemic lupus erythematosus overlap syndrome with predominant polyarthritis. On examination, painful and enlarged cervical, inguinal, and abdominal lymph nodes were found. Laboratory analyses revealed leucocytosis of 18.7 G/L and elevated C-reactive protein of 40.3mg/L (normal range <5mg/L). Sonography and computed tomography showed a massive retroperitoneal lymph node bulk with central necrotic transformation (A), ascites, and splenomegaly with multiple abscesses (B). No pleural effusions or pulmonary infiltrates were present at first. Despite broad antibiotic treatment, the patient rapidly deteriorated and was admitted to ICU on day 10. She developed multi-organ failure (SOFA score 8 points), necessitating fluid resuscitation, norepinephrine therapy, and invasive mechanical ventilation. Because of the critical condition of the patient, several investigations were performed simultaneously. Initial tests including blood, urine, bronchial lavage and ascites cultures, as well as repeated interferon-gamma release assays, HIV, Galactomannan and beta-D-glucan were negative. Ziehl-Neelsen staining of bronchial lavage and ascites were negative. Microscopic differential blood count was unremarkable, but adenosine deaminase in plasma was elevated (46 U/L, normal range <15 U/L). One enlarged inguinal lymph node was removed because aggressive lymphoma was suspected in the 3 Tuberculosis Sepsis after Tocilizumab differential diagnosis. Histopathological work-up revealed no signs of malignant cells, but granulomas surrounded by epithelioid cells (C, 10x magnification). Serological tests for Bartonella henselae and quintana, Toxoplasma gondii, Leptospira, Francisella tularensis, and Yersinia were negative. However, Ziehl-Neelsen staining showed acid-fast rods (D, 60x magnification), and mycobacterial PCR detected high concentrations of Mycobacterium tuberculosis DNA complexes in the explanted inguinal lymph node. On 16S pan-bacterial PCR analyses no other bacterial species were found. Therefore, the diagnosis of sepsis due to disseminated tuberculosis was made, and treatment was switched to tuberculostatic chemotherapy with isoniazid, rifampicin, pyrazinamide and ethambutol on day 15. The patient slowly recovered with targeted chemotherapy and was discharged from ICU fully oriented on day 23. Five to eight weeks later, cultures from multiple locations, including specimens from the inguinal lymph node and bronchial lavage, showed growth of Mycobacterium tuberculosis, which were pan-sensible on antibiotic susceptibility testing.

Finally, an obtained third-party history from the patient's sister provided the information of possible tuberculosis during childhood, which was not recalled by the patient herself. She had recently not been abroad and had no known contact to an infected person. Before treatment with tocilizumab was started, interferon-gamma assay tests were negative. Nevertheless, we suppose that reactivation of latent tuberculosis took place in our patient, as new-onset infection is highly unlikely in a low-prevalence area such as Austria. Thus, this case also points to the fact that interferon-gamma release assays may be false negative both before treatment with tocilizumab, and during disseminated tuberculosis (4).

In summary, fulminant sepsis due to Mycobacterium tuberculosis infection may be triggered not only by tumor necrosis factor alpha inhibitors (5), but also by IL-6R antagonists such as tocilizumab. High clinical suspicion for reactivation of latent tuberculosis should be maintained even when interferon-gamma assays are negative before and during IL-6R antagonist therapy. 6 Tuberculosis Sepsis after Tocilizumab

An Update on Current